Cosylab and Heron: A Strategic Alliance to Globalize Advanced Cancer Care

LJUBLJANA, Slovenia – June 10, 2026 – Today’s announcement of a Letter of Intent between Slovenia’s Cosylab and Taiwan-based Heron Neutron Medical Corp. is far more than a routine corporate handshake. On the surface, it’s a strategic framework to deploy advanced cancer-fighting technology. But look deeper, and you see the blueprint for solving one of the most persistent challenges in medical innovation: bridging the gap between a groundbreaking device and its successful, scalable, real-world application. The partnership aims to accelerate the global adoption of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), a treatment with profound potential for notoriously difficult cancers. By wedding Heron’s specialized hardware with Cosylab’s mission-critical software expertise, this alliance isn't just entering a market; it's attempting to define the operational standard for it.

The Cellular Battlefield: BNCT's Promise and Peril

Boron Neutron Capture Therapy represents a paradigm of precision in oncology. It is a binary therapy that attacks cancer at the cellular level. First, a patient is infused with a boron-10 compound engineered to accumulate preferentially in tumor cells. Hours later, the tumor area is irradiated with a beam of low-energy neutrons. These neutrons are harmless to healthy tissue but trigger a powerful, localized nuclear reaction when captured by the boron atoms inside the cancer cells. The reaction releases particles that destroy the cancer cell from within, a microscopic explosion with a blast radius so small—just 5 to 9 micrometers—that it spares adjacent healthy cells. This makes BNCT an exceptionally promising weapon against recurrent, inoperable, or treatment-resistant tumors like glioblastoma and certain head and neck cancers, where collateral damage from conventional radiation is a primary concern.

For decades, the primary obstacle to BNCT’s widespread use was its reliance on nuclear reactors as a neutron source, confining the therapy to a handful of research institutions. The advent of Accelerator-Based BNCT (AB-BNCT) systems, like those developed by Heron, changes the equation. These systems are smaller, safer, and more cost-effective, designed for installation within hospital environments. Yet, this hardware breakthrough introduces a new set of complexities. An accelerator is not a plug-and-play device. It requires exquisitely precise control systems to generate a stable neutron beam, integrate with treatment planning software, manage patient positioning, and ensure every step of the clinical workflow is safe, repeatable, and compliant with stringent medical regulations. This is the chasm between a working machine and a viable medical product.

Forging the Missing Link: Hardware Meets Mission-Critical Software

The Cosylab-Heron LOI is a direct response to this challenge. Heron Neutron Medical Corp., spun out of research from Taiwan's top academic institutions, provides the core technology: an end-to-end AB-BNCT platform. The company has already gained significant traction, securing a NT$1.2 billion order to establish a treatment center at Taipei Veterans General Hospital. However, scaling this success globally requires a different order of expertise.

This is where Cosylab becomes the partnership’s critical force multiplier. With over two decades of experience taming the world's most complex machines—from particle accelerators at CERN to fusion reactors—Cosylab specializes in the software and control systems that make such hardware function reliably. Their role is to provide the central nervous system for Heron's platform. This is not merely user-interface design; it involves developing the regulatory-compliant (ISO 13485, IEC 62304) software that choreographs the entire treatment, from beam generation to dose delivery. As one industry observer noted, sophisticated medical hardware is only as effective as the software that controls it. Cosylab's proven track record, including recent partnerships with the Mayo Clinic for carbon ion therapy and the launch of its own FDA-cleared treatment planning system, PlanOne™, provides the credibility needed to assure hospitals of a robust, integrated, and certifiable solution.

"This collaboration reinforces Cosylab`s strategic focus on advancing radiation therapy technologies and expanding our reach in the Asia-Pacific region and beyond," said Mark Pleško, CEO of Cosylab. This statement underscores a strategy of leveraging deep technical expertise to enable broader market access for hardware innovators.

The Eastern Gambit: Targeting Asia's Burgeoning Oncology Market

The partnership’s explicit focus on the Asia-Pacific (APAC) region is a calculated and astute strategic move. APAC is not only the world's fastest-growing oncology market but is also at the forefront of BNCT adoption. Japan already offers a reimbursed treatment framework for head and neck cancer, and countries like Taiwan and South Korea are rapidly building out their capabilities. This momentum is fueled by grim necessity: rising cancer incidence, aging populations, and increasing healthcare investment create a fertile ground for advanced therapies.

By combining forces, Heron gains a pathway to international markets through Cosylab’s global footprint and integration experience, while Cosylab solidifies its position as the go-to software partner in the most dynamic radiotherapy market in the world. "Working with Cosylab will strengthen our cross-regional capabilities and support the rapid scaling of AB-BNCT solutions in markets worldwide," noted Shen Hsiao-Lien, General Manager of Heron Neutron Medical Corp. This synergy is designed to create a turnkey solution that is more attractive to hospital systems across Asia and, eventually, the globe, reducing the implementation risk and timeline for institutions looking to adopt this cutting-edge technology.

From Lab to Ledger: The Economic Realities of a Nascent Therapy

While the clinical promise is compelling, the business case must be equally sound. The global BNCT market, though nascent, is projected to experience explosive growth. Analyst estimates vary, but they consistently point to a market expanding from a few hundred million dollars today to several billion by the early 2030s, with Compound Annual Growth Rates (CAGRs) forecasted between 16% and a staggering 50%. The Cosylab-Heron alliance is positioned to capture a significant share of this expansion.

For hospitals, the initial investment in an AB-BNCT system is substantial. The partnership’s value proposition is its ability to de-risk that investment. By providing a pre-integrated, robustly controlled system, they can shorten the path from installation to the first patient treatment, accelerating the return on investment. The collaboration transforms the offering from a collection of complex components into a cohesive, functional, and supportable clinical solution. This move from a technology-push to a market-pull strategy, where the solution is designed to meet the operational and financial needs of the healthcare provider, is critical for driving the widespread clinical adoption that both companies—and patients—are counting on.